Regeneron Pharmaceuticals Inc vs Clear Secure Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $674.04 (market cap $70.79B), while Clear Secure Inc trades at $56.96 (market cap $5.73B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 12.4× Clear Secure Inc's market cap, and Clear Secure Inc pays the higher dividend (1.05%). Which is the better fit depends on your goals.
| REGN | YOU | |
|---|---|---|
Market Cap | $70.79B | $5.73B |
Sector | Health | Technology |
52-Week High | $812.27 | $62.36 |
52-Week Low | $545.46 | $28.84 |
Enterprise Value | $64.74B | $5.04B |
Dividend Yield | 0.56% | 1.05% |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Clear Secure (YOU) trades at $57.18, up 2.05% with a bullish technical outlook. The stock shows strong profitability with 65.48% gross margins and 81.15% ROE, though valuation multiples appear elevated with a P/E of 45.74. Recent earnings beat expectations in Q1 2026 with $0.38 EPS versus $0.35 expected. The company continues expanding airport partnerships and launched AWS integration for contact center verification in June 2026.
Growth prospects remain positive with revenue projected to reach $942 million in 2026, but high valuation multiples and mixed analyst ratings (44% Buy, 44% Hold) suggest cautious optimism. Key risks include execution of expansion plans and competitive pressures in identity verification markets. The consensus price target of $56.67 offers limited upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →